Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 19/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 10/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | IGF1R | P08069 | 1/20 | 0.73 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.73 |
| ▸ | TSSK2 | Q96PF2 | 1/20 | 0.73 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13764316 | 1.00 | CHEK1 (1.00) | CHEK1MAPKAPK2JAK2LCKIGF1R | |
| SCHEMBL13258870 | 0.91 | CHEK1 (1.00) | CHEK1MAPKAPK2JAK2LCKIGF1R | |
| SCHEMBL13258873 | 0.89 | CHEK1 (1.00) | CHEK1MAPKAPK2JAK2LCKIGF1R | |
| SCHEMBL13258885 | 0.89 | CHEK1 (0.84) | CHEK1MAPKAPK2JAK2LCKIGF1R | |
| SCHEMBL13258969 | 0.87 | CHEK1 (1.00) | CHEK1MAPKAPK2JAK2LCKIGF1R | |
| SCHEMBL13258891 | 0.86 | CHEK1 (0.80) | CHEK1MAPKAPK2JAK2LCKIGF1R | |
| SCHEMBL13258889 | 0.85 | CHEK1 (0.74) | CHEK1MAPKAPK2JAK2LCKIGF1R | |
| SCHEMBL13258882 | 0.85 | CHEK1 (0.81) | CHEK1MAPKAPK2JAK2LCKIGF1R | |
| SCHEMBL13258755 | 0.85 | CHEK1 (0.80) | CHEK1MAPKAPK2JAK2LCKIGF1R | |
| SCHEMBL13258967 | 0.84 | CHEK1 (0.78) | CHEK1MAPKAPK2JAK2LCKIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010088368-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20090175852-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090175852-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-7557104-B2 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557104-B2 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080027063-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
| US-20080027063-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
| WO-2007145921-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027063-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | CHEK1, CHEK2, CDKN1A | CHEK1 1/4885MAPKAPK2 43/4885JAK2 71/4885 |
| US-20090175852-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | CHEK1, CHEK2, CDKN1A | CHEK1 1/4885MAPKAPK2 43/4885JAK2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.